- Home
- NEWT vs CLLS Comparison
NEWT vs CLLS Comparison
Compare NEWT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- CLLS
- Stock Information
- Founded
- NEWT 1998
- CLLS 1999
- Country
- NEWT United States
- CLLS France
- Employees
- NEWT N/A
- CLLS N/A
- Industry
- NEWT Major Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- CLLS Health Care
- Exchange
- NEWT Nasdaq
- CLLS Nasdaq
- Market Cap
- NEWT 300.3M
- CLLS 299.0M
- IPO Year
- NEWT N/A
- CLLS 2007
- Fundamental
- Price
- NEWT $10.26
- CLLS $3.61
- Analyst Decision
- NEWT Hold
- CLLS Buy
- Analyst Count
- NEWT 4
- CLLS 1
- Target Price
- NEWT $13.25
- CLLS $8.00
- AVG Volume (30 Days)
- NEWT 222.7K
- CLLS 135.1K
- Earning Date
- NEWT 10-29-2025
- CLLS 11-07-2025
- Dividend Yield
- NEWT 7.47%
- CLLS N/A
- EPS Growth
- NEWT 32.88
- CLLS N/A
- EPS
- NEWT 2.23
- CLLS N/A
- Revenue
- NEWT $380,364,000.00
- CLLS $82,551,000.00
- Revenue This Year
- NEWT N/A
- CLLS N/A
- Revenue Next Year
- NEWT $12.56
- CLLS $58.00
- P/E Ratio
- NEWT $4.56
- CLLS N/A
- Revenue Growth
- NEWT 20.21
- CLLS 129.04
- 52 Week Low
- NEWT $9.12
- CLLS $1.10
- 52 Week High
- NEWT $15.41
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- NEWT 39.01
- CLLS 53.20
- Support Level
- NEWT $10.07
- CLLS $3.12
- Resistance Level
- NEWT $10.36
- CLLS $3.79
- Average True Range (ATR)
- NEWT 0.39
- CLLS 0.20
- MACD
- NEWT -0.00
- CLLS -0.00
- Stochastic Oscillator
- NEWT 17.61
- CLLS 68.92
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.